Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for FibroBiologics Inc. (FBLG : NSDQ)

• Company Description    FibroBiologics Inc. is a cell therapy, regenerative medicine company developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. FibroBiologics Inc. is based in HOUSTON. Number of Employees: 15

• Price / Volume Information    Yesterday's Closing Price: $0.33 Daily Weekly Monthly 20 Day Moving Average: 952,682 shares Shares Outstanding: 67.60 (millions) Market Capitalization: $22.21 (millions) Beta: -0.69 52 Week High: $1.53 52 Week Low: $0.22 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -0.96% -0.10% 12 Week 24.61% 24.46% Year To Date 46.11% 45.40%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 455 E. MEDICAL CENTER BLVD SUITE 300 - HOUSTON,TX 77598 USA ph: 281-671-5150 fax: - fibrobiologicsir@russopr.com http://www.fibrobiologics.com

• General Corporate Information    Officers Pete O'Heeron - Chief Executive Officer and Chairperson Jason D. Davis - Chief Financial Officer Richard Cilento - Director Stacy Coen - Director Robert E. Hoffman - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 31573L105 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 12/01/25 Next Expected EPS Date: 05/13/26 Share - Related Items Shares Outstanding: 67.60 Most Recent Split Date: (:1) Beta: -0.69 Market Capitalization: $22.21 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.07 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.28 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 2.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 05/13/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 3.55 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 66.67% vs. Previous Quarter: 76.92% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 12/31/25 - -785.84 09/30/25 - -1,219.18 06/30/25 - -710.25 ROA 12/31/25 - -170.69 09/30/25 - -146.48 06/30/25 - -118.02 Current Ratio 12/31/25 - 3.61 09/30/25 - 0.78 06/30/25 - 0.93 Quick Ratio 12/31/25 - 3.61 09/30/25 - 0.78 06/30/25 - 0.93 Operating Margin 12/31/25 - - 09/30/25 - - 06/30/25 - - Net Margin 12/31/25 - - 09/30/25 - - 06/30/25 - - Pre-Tax Margin 12/31/25 - - 09/30/25 - - 06/30/25 - - Book Value 12/31/25 - 0.09 09/30/25 - 0.00 06/30/25 - 0.02 Inventory Turnover 12/31/25 - - 09/30/25 - - 06/30/25 - - Debt-to-Equity 12/31/25 - 0.00 09/30/25 - 0.00 06/30/25 - 0.00 Debt-to-Capital 12/31/25 - 0.00 09/30/25 - 0.00 06/30/25 - 0.00

Powered by Zacks Investment Research ©